Novartis job cuts to heavily impact management roles
Under construction: the new Novartis Pavilion in Basel.
Keystone / Georgios Kefalas
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve staff in leadership positions, the company said on Monday.
For these executive roles, the consultation process has been finalised, and the first individuals concerned will be informed “in the coming weeks”, said the head of Novartis Switzerland Matthias Leuenberger at a media event in Zurich.
While Switzerland is no stranger to job cuts, such a big lay-off of management level staff is somewhat unprecedented in the country, a spokesperson for the Swiss Employees Association told the NZZ newspaper on Tuesday.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The cuts – part of a worldwide restructuring that will see 8,000 jobs shelved – are part of a streamlining that will see the merger of two previously separate Novartis divisions, Innovative Pharmaceuticals and Cancer Drugs.
The company also wants to simplify its global functions in finance, human resources, legal and communications, with the goal of saving at least CHF1 billion ($1.04 billion) by 2024.
The Swiss cuts will probably not come into effect until summer 2023, due to the terms of the employee contracts, Leuenberger said on Monday. He added that while some staff are concerned about the layoffs, they are “neither frustrated nor angry”, and apparently regard the situation as an opportunity to re-orient themselves.
Leuenberger also said that fewer staff will have the option of taking early retirement compared to a previous bout of layoffs in 2018.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
This content was published on
With over 100,000 jobs listed as vacant in the first quarter of 2022, staff shortages are reaching record levels in Switzerland.
This content was published on
Around 1,500 jobs are affected in production and 700 in services. Novartis currently employs 13,000 people across Switzerland.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.